{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:13:45Z","timestamp":1772133225055,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Roche-Genentech"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cytori"},{"name":"Chemocentryx"},{"name":"Corbus"},{"name":"Formation Biologics"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.rdc.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T15:13:05Z","timestamp":1562080385000},"page":"379-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis"],"prefix":"10.1016","volume":"45","author":[{"given":"Sebastian E.","family":"Sattui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.rdc.2019.04.006_bib1","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.40313","article-title":"The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in olmsted county, minnesota: a\u00a0twenty-year us population-based study","volume":"69","author":"Berti","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2019.04.006_bib2","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","article-title":"Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"30","author":"Watts","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"5091","key":"10.1016\/j.rdc.2019.04.006_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"issue":"7","key":"10.1016\/j.rdc.2019.04.006_bib4","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/ard.2007.071936","article-title":"Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force","volume":"67","author":"Mukhtyar","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.04.006_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine"},{"issue":"27","key":"10.1016\/j.rdc.2019.04.006_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM197112302852701","article-title":"Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis","volume":"285","author":"Fauci","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.rdc.2019.04.006_bib7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM197104292841703","article-title":"Cyclophosphamide therapy in Wegener's granulomatosis","volume":"284","author":"Novack","year":"1971","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2019.04.006_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.rdc.2019.04.006_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2019.04.006_bib10","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.04.006_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.rdc.2019.04.006_bib12","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A\u00a0prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2019.04.006_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2019.04.006_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/978-1-4757-9182-2_87","article-title":"Effectiveness of cyclophosphamide pulse treatment in Wegener's granulomatosis","volume":"336","author":"Reinhold-Keller","year":"1993","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.rdc.2019.04.006_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0002-9343(90)90367-M","article-title":"Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide","volume":"89","author":"Hoffman","year":"1990","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.rdc.2019.04.006_bib16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.rdc.2019.04.006_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.04.006_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2019.04.006_bib19","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1136\/ard.2010.131953","article-title":"Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2019.04.006_bib20","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2019.04.006_bib21","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R","article-title":"Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis","volume":"43","author":"Langford","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2019.04.006_bib22","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2019.04.006_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","article-title":"Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients","volume":"57","author":"Cohen","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2019.04.006_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.rdc.2019.04.006_bib25","doi-asserted-by":"crossref","first-page":"e0185880","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.rdc.2019.04.006_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.rdc.2019.04.006_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2019.04.006_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2019.04.006_bib29","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.39104","article-title":"Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids","volume":"67","author":"Miloslavsky","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2019.04.006_bib30","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2019.04.006_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2019.04.006_bib32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.04.006_bib33","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2019.04.006_bib34","first-page":"386","article-title":"Rituximab or azathioprine maintenance in ANCA-associated vasculitis","volume":"372","author":"Pagnoux","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2019.04.006_bib35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.rdc.2019.04.006_bib36","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.rdc.2019.04.006_bib37","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2019.04.006_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"10.1016\/j.rdc.2019.04.006_bib39","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.rdc.2019.04.006_bib40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.20240","article-title":"Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis","volume":"51","author":"Langford","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2019.04.006_bib41","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 10","key":"10.1016\/j.rdc.2019.04.006_bib42","article-title":"The effects of plasma exchange and reduced-dose glucocorticoids during remission-induction for treatment of severe ANCA-associated vasculitis","volume":"70","author":"Walsh","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2019.04.006_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.rdc.2017.06.006","article-title":"Central nervous system disease in antineutrophil cytoplasmic antibodies-associated vasculitis","volume":"43","author":"Graf","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.rdc.2019.04.006_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10067-017-3835-y","article-title":"Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study","volume":"37","author":"Fragoulis","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2019.04.006_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/01.md.0000200166.90373.41","article-title":"Central nervous system involvement in Wegener granulomatosis","volume":"85","author":"Seror","year":"2006","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.rdc.2019.04.006_bib46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.autrev.2017.07.007","article-title":"Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): report of 26 patients and review of the literature","volume":"16","author":"Andre","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.rdc.2019.04.006_bib47","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/acr.22311","article-title":"Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegener's)","volume":"66","author":"Lally","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2019.04.006_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.rdc.2019.04.006_bib49","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.rdc.2019.04.006_bib50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181af35a5","article-title":"Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis","volume":"88","author":"Neumann","year":"2009","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.rdc.2019.04.006_bib51","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.rdc.2019.04.006_bib52","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1930033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1930033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:18:03Z","timestamp":1760181483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X1930033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0889857X1930033X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2019.04.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}